Benign Prostatic Hyperplasia Therapeutics Market Set to Record Exponential Growth by 2019

Benign Prostatic Hyperplasia (BPH) or benign prostatic hypertrophy, is a urological disorder that involves proliferation of the cellular components of the prostrate. BPH is the most common form of neoplasm in men. BPH results in the formation of large nodes and nodules in the periurethral region of the prostate. The significantly large nodules compresses the urethral canal that causes to partial or complete urinary tract obstruction which inhibits the normal flow of urine. Obstruction in the urinary tract further leads to complications such as urinary retention, urinary tract infections and urinary hesitancy.

Geographically, North America is the leading market due to high prevalence rate of benign prostatic hyperplasia and lower urinary tract symptoms (LUTS). Various studies reports that 90% of men in the U.S., aged between 45 and 80 years suffer from some type of LUTS and approximately 14 million men in the U.S. have symptoms of BPH. Asia-Pacific is also expected to witness a significant growth due to the rise in various urological disorders and complications. However, BPH tends to be more progressive in African-American men owing to the presence of high testosterone level in their body.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1872

Rise in geriatric population is expected to be one of the major driver that might drive the market. Additionally, increased awareness for prostate cancer and other urological disorders, are also expected to fuel the growth of the global BPH therapeutics market. However, high adoption rate of minimally invasive surgeries such as transurethral microwave thermotherapy (TUMT), laparoscopic prostatectomy and transurethral needle ablation (TUNA) might impede the growth of the BPH therapeutics market.

Some of the key players in the benign prostatic hyperplasia (BPH) therapeutics Market are AEternaZentaris Inc., Astellas Pharma Inc., Eli Lilly and Company, EndoCeutics, Inc., IntelGenx Technologies Corp., Ipsen S.A., Nymox Pharmaceutical Corporation, Protox Therapeutics Inc. and Quest PharmaTech Inc.

Request to View ToC of the report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1872

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Persistence Market Research (Pmr) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.